



**Edwards Lifesciences Corporation**  
One Edwards Way · Irvine, CA USA · 92614  
Phone: 949.250.2500 · Fax: 949.250.2525  
[www.edwards.com](http://www.edwards.com)

## **FOR IMMEDIATE RELEASE**

**Media Contact:** Rich Ferreira, 949-250-5782

**Investor Contact:** Mark Wilterding, 949-250-6826

## **EDWARDS LAUNCHES FORESIGHT TECHNOLOGY ON HEMOSPHERE PLATFORM**

**IRVINE, Calif., August 29, 2019** -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for a smart cable enabling compatibility between the company's ForeSight tissue oximetry (brain oxygenation) sensors and HemoSphere advanced monitoring platform.

The ForeSight sensor is Edwards' latest non-invasive offering and is part of a unique set of smart recovery tools available on a single monitor. Edwards obtained the ForeSight technology in April 2019 through an acquisition with CAS Medical Systems, Inc. (CASMED), and the integration of the ForeSight sensor with the HemoSphere monitor is a result of a multi-year collaboration between both companies that demonstrates a shared commitment to helping patients.

"During surgical procedures where patients can not convey symptoms of reduced brain perfusion due to general anesthesia or sedation, decreased oxygen levels in the brain can have lasting effects and could result in complications as well as increased time spent in the hospital," said Charles Hogue, M.D., Professor of Anesthesiology and Chairman of the Department of Anesthesiology at Northwestern University Feinberg School of Medicine in Chicago, IL. "Combining advanced hemodynamic monitoring with tissue oximetry provides a more complete view of patients' oxygen levels and oxygen use, allowing clinicians to optimize care for their patients throughout a procedure."

Decreases in oxygen levels in the brain are associated with complications such as cognitive dysfunction and delirium, and can result in extended time on ventilation machines or in intensive

care units. Cerebral oximetry is the only non-invasive indicator of brain oxygenation available to anesthesiologists and surgical teams. As part of the HemoSphere platform, ForeSight sensors can be utilized in combination with other advanced monitoring and decision-support tools to provide a comprehensive view of a patient's hemodynamic status.

“Understanding the relationship between the heart and the brain can provide valuable patient insights to support decision making during a surgical procedure,” said Katie Szyman, Edwards’ corporate vice president, critical care. “With the addition of the ForeSight sensors to Edwards’ most modern platform, HemoSphere, we can offer clinicians a broad range of smart hemodynamic management solutions to help improve patient care.”

*Dr. Hogue is a consultant to Edwards Lifesciences.*

### **About Edwards Lifesciences**

Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit [www.Edwards.com](http://www.Edwards.com) and follow us on Twitter @EdwardsLifesci.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements by Dr. Hogue and Ms. Szyman and statements regarding expected product benefits, patient outcomes, future plans related to the product lines, objectives and expectations and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors including but not limited to unexpected outcomes after more expanded clinical experience, unexpected changes or delays related to product supply, potentials for unexpected regulatory or quality developments, competitive dynamics, or unexpected delays or changes in patient access, litigation or clinician acceptance. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2018.

Edwards, Edwards Lifesciences, the stylized E logo, ForeSight and HemoSphere are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.

###